Arterius Limited products

ArterioSorb is produced from the FDA approved polymer, PLLA, which is already universally approved for use in cardiovascular stents, sutures and orthopaedic applications. ArterioSorb is a tubular stent with closed-cell (with connectors for strength) and open-cell (with fewer connectors for flexibility) modules and increasing cell size as one moves away from the centre: The smaller cells at the centre provide the greatest radial support and higher drug delivery, where the stenosis is most severe, while the larger cells provide greater flexibility for ease of implantation.

Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to: Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES); Come in a range of sizes and lengths. Provide equivalent mechanical performance (radial strength) to the best-in-classDrug Eluting Stent (DES) products. Generate fewer clinical adverse events than current Drug Eluting Stent (DES). Be resorbed within 24 months leaving nothing behind which might complicate future revascularisations. Overcome the high in-stent late lumen loss (narrowing of the vessel once the stent has dissolved) which has limited the adoption of first generation products.